STOCK TITAN

Ascendis Pharma A/S - ASND STOCK NEWS

Welcome to our dedicated news page for Ascendis Pharma A/S (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma A/S.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ascendis Pharma A/S's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ascendis Pharma A/S's position in the market.

Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) announced new analyses from the ACcomplisH trial of TransCon CNP, the first investigational product to demonstrate improvements in health-related quality of life and disease impacts in children with achondroplasia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
-
Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) announced positive topline results from foresiGHt, its Phase 3 trial evaluating TransCon hGH for adults with growth hormone deficiency. The trial demonstrated statistically significant reduction in trunk fat and increase in total body lean mass compared to placebo, with generally safe and well-tolerated outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
-
Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) has announced that the U.S. FDA has accepted for review the Company’s resubmitted NDA for TransCon PTH for the treatment of adult patients with hypoparathyroidism. The PDUFA goal date is set for May 14, 2024. TransCon PTH is an investigational prodrug of parathyroid hormone (PTH [1-34]) for adult patients with hypoparathyroidism.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) has entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan. Ascendis will receive $70 million upfront, with additional development and regulatory milestones of up to $175 million, transfer pricing, and commercial milestones. The company is also eligible to receive royalties on net sales in Japan, of up to mid-20’s percent, varying by product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.12%
Tags
partnership
-
Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) announced that the European Commission granted marketing authorization for YORVIPATH (palopegteriparatide) as a replacement therapy for adults with chronic hypoparathyroidism. YORVIPATH, a prodrug of parathyroid hormone (PTH 1-34), will be launched in Germany in January 2024. The approval follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of YORVIPATH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
-
Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) has resubmitted its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) to the U.S. Food & Drug Administration (FDA) for the treatment of adults with hypoparathyroidism. The resubmission follows a Type A meeting held with the FDA in late August. This announcement highlights the company's commitment to providing a treatment option addressing the underlying disease pathophysiology for patients living with hypoparathyroidism. The PR emphasizes the positive results from ongoing clinical trials of TransCon PTH, showing significant health and quality-of-life improvements for the majority of patients, with no new safety concerns identified in follow-up reaching up to four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
none
Rhea-AI Summary
ASND: Ascendis Pharma Announces European Commission Decision for TransCon™ PTH Expected This Month, SKYTROFA Q3 Revenue Increases to €47.0 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
-
Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) will report its Q3 2023 financial results and provide a business update on November 7, 2023. They also plan to resubmit their NDA for TransCon PTH for adults with hypoparathyroidism to the FDA before mid-November 2023. A conference call and webcast will be held on the same day to discuss the financial results and operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
-
Rhea-AI Summary
Ascendis Pharma presents updated data from Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ at ESMO 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
none
Rhea-AI Summary
Ascendis Pharma shares 52-week data from Phase 3 PaTHway Trial of TransCon PTH
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
Ascendis Pharma A/S

Nasdaq:ASND

ASND Rankings

ASND Stock Data

8.01B
56.16M
0.76%
107.81%
5.91%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Denmark
Tuborg Boulevard 5

About ASND

ascendis pharma a/s is a biotechnology company located in 12 tuborg blvd., hellerup, capital region of denmark, denmark.